Samil Pharmaceutical Co.,Ltd

KOSE:A000520 Stock Report

Market Cap: ₩294.7b

Samil PharmaceuticalLtd Past Earnings Performance

Past criteria checks 0/6

Samil PharmaceuticalLtd's earnings have been declining at an average annual rate of -4.6%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 13.8% per year.

Key information

-4.6%

Earnings growth rate

-4.0%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate13.8%
Return on equity-0.7%
Net Margin-0.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Mar 21
Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Recent updates

Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Jan 03
Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Some Samil Pharmaceutical Co.,Ltd (KRX:000520) Shareholders Look For Exit As Shares Take 27% Pounding

Nov 18
Some Samil Pharmaceutical Co.,Ltd (KRX:000520) Shareholders Look For Exit As Shares Take 27% Pounding

Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking

Sep 13
Optimistic Investors Push Samil Pharmaceutical Co.,Ltd (KRX:000520) Shares Up 29% But Growth Is Lacking

We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt

Sep 11
We Think Samil PharmaceuticalLtd (KRX:000520) Is Taking Some Risk With Its Debt

Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking

Jul 29
Investor Optimism Abounds Samil Pharmaceutical Co.,Ltd (KRX:000520) But Growth Is Lacking

Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?

May 24
Does Samil PharmaceuticalLtd (KRX:000520) Have A Healthy Balance Sheet?

There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Mar 30
There's Reason For Concern Over Samil Pharmaceutical Co.,Ltd's (KRX:000520) Massive 29% Price Jump

Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Mar 21
Samil PharmaceuticalLtd's (KRX:000520) Earnings Are Of Questionable Quality

Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Apr 01
Here's Why Samil PharmaceuticalLtd (KRX:000520) Has A Meaningful Debt Burden

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Mar 11
Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 141% Total Return On Their Investment

Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

Feb 15
Are Dividend Investors Getting More Than They Bargained For With Samil Pharmaceutical Co.,Ltd's (KRX:000520) Dividend?

Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

Jan 20
Should You Be Concerned About Samil Pharmaceutical Co.,Ltd's (KRX:000520) ROE?

Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Dec 24
Why It Might Not Make Sense To Buy Samil Pharmaceutical Co.,Ltd (KRX:000520) For Its Upcoming Dividend

Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

Dec 09
Samil PharmaceuticalLtd (KRX:000520) Has Gifted Shareholders With A Fantastic 221% Total Return On Their Investment

What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

Nov 18
What Is The Ownership Structure Like For Samil Pharmaceutical Co.,Ltd (KRX:000520)?

Revenue & Expenses Breakdown

How Samil PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A000520 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24212,424-1,17467,2295,828
30 Jun 24210,733-1,15564,5325,913
31 Mar 24204,905-78661,4615,870
31 Dec 23196,3461,66459,9625,601
30 Sep 23189,2932,60059,6385,249
30 Jun 23183,0601,33659,7524,342
31 Mar 23179,56634358,9073,553
31 Dec 22179,676-2858,5192,907
30 Sep 22170,510-4,98955,3642,359
30 Jun 22158,910-4,74051,2262,617
31 Mar 22147,877-5,61948,0472,948
31 Dec 21134,247-5,34743,7632,971
30 Sep 21129,974-2,76141,6343,007
30 Jun 21127,287-1,32740,7093,007
31 Mar 21122,79313238,9602,593
31 Dec 20122,9991,34137,9893,007
30 Sep 20123,11494036,5103,185
30 Jun 20122,30872937,0872,847
31 Mar 20123,1021,42937,4613,183
31 Dec 19121,10778637,4533,060
30 Sep 19114,364-1,25137,7923,060
30 Jun 19107,856-3,36837,0172,969
31 Mar 19102,805-6,46137,4982,619
31 Dec 1894,600-8,56337,3732,182
30 Sep 1896,882-5,16537,5802,026
30 Jun 1894,916-4,60536,9252,087
31 Mar 1892,286-2,79736,1681,987
31 Dec 1792,038-1,26736,7341,961
30 Sep 1790,658-1,43435,7921,938
30 Jun 1792,11889835,3571,605
31 Mar 1794,68594835,8821,447
31 Dec 1696,75888735,6671,254
30 Sep 1694,01030635,3091,047
30 Jun 1692,62514034,9091,136
31 Mar 1688,65655333,5031,121
31 Dec 1588,13658833,6881,119
30 Sep 1585,795-2,98635,2501,457
30 Jun 1585,439-6,17036,9031,831
31 Mar 1585,849-10,17939,2252,477
31 Dec 1485,461-11,19039,0112,790
30 Sep 1487,6831,14837,9982,841
30 Jun 1487,5453,60137,0612,126
31 Mar 1489,2077,19134,5622,182

Quality Earnings: A000520 is currently unprofitable.

Growing Profit Margin: A000520 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A000520 is unprofitable, and losses have increased over the past 5 years at a rate of 4.6% per year.

Accelerating Growth: Unable to compare A000520's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A000520 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.3%).

Return on Equity

High ROE: A000520 has a negative Return on Equity (-0.67%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 09:09
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Samil Pharmaceutical Co.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sun-Jae HeoSK Securities Co., Ltd.